Length of human immunodeficiency virus disease and not immune status is a risk factor for development of anal carcinoma

Shawn P. Fagan, Charles F. Bellows, Daniel Albo, Maria Rodriquez-Barradas, Mark Feanny, Samir S. Awad, David H. Berger

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: The anal epithelium is subject to dysplastic change in patients with human immunodeficiency virus (HIV). We sought to determine if the duration of HIV disease or the patient's immune status were associated with the development of anal carcinoma. Methods: HIV-positive patients diagnosed with anal neoplasms were reviewed. Statistical analysis was performed via an unpaired Student t test and the Fisher exact test. Results: Fourteen patients were identified, 7 with anal intraepithelial neoplasms (group 1) and 7 with anal carcinoma (group 2). Human papillomavirus was detected in 100% of patients in group 1 and in 67% of patients in group 2. There was no significant difference in the level of immunosuppression as assessed by the CD4 counts (266.9 ± 48.5 vs. 274.7 ± 92.0 cell/cμl; P = .94) and viral loads (19,243 ± 18,034 vs. 67,140 ± 39,570 RNA/mL; P = .29) between groups 1 and 2, respectively. Group 2 had been HIV positive for a significantly longer period of time (12.6 ± 2.3 y) compared with group 1 (5.9 ± 2.0 y, P = .05). Conclusions: The most significant factor for the development of invasive anal carcinoma in patients with HIV is duration of disease. As a result of improved long-term survival secondary to new HIV therapy, anal invasive carcinoma will become an increasing problem.

Original languageEnglish (US)
Pages (from-to)732-735
Number of pages4
JournalAmerican Journal of Surgery
Volume190
Issue number5
DOIs
StatePublished - Nov 1 2005
Externally publishedYes

Fingerprint

Virus Diseases
HIV
Carcinoma
Anus Neoplasms
Carcinoma in Situ
CD4 Lymphocyte Count
Viral Load
Immunosuppression
Epithelium
RNA
Students
Survival

Keywords

  • Anal carcinoma
  • Bowen's disease
  • HIV
  • Immune status

ASJC Scopus subject areas

  • Surgery

Cite this

Length of human immunodeficiency virus disease and not immune status is a risk factor for development of anal carcinoma. / Fagan, Shawn P.; Bellows, Charles F.; Albo, Daniel; Rodriquez-Barradas, Maria; Feanny, Mark; Awad, Samir S.; Berger, David H.

In: American Journal of Surgery, Vol. 190, No. 5, 01.11.2005, p. 732-735.

Research output: Contribution to journalArticle

Fagan, Shawn P. ; Bellows, Charles F. ; Albo, Daniel ; Rodriquez-Barradas, Maria ; Feanny, Mark ; Awad, Samir S. ; Berger, David H. / Length of human immunodeficiency virus disease and not immune status is a risk factor for development of anal carcinoma. In: American Journal of Surgery. 2005 ; Vol. 190, No. 5. pp. 732-735.
@article{530d636ca17a4d139b4847fc7fc3c6b9,
title = "Length of human immunodeficiency virus disease and not immune status is a risk factor for development of anal carcinoma",
abstract = "Background: The anal epithelium is subject to dysplastic change in patients with human immunodeficiency virus (HIV). We sought to determine if the duration of HIV disease or the patient's immune status were associated with the development of anal carcinoma. Methods: HIV-positive patients diagnosed with anal neoplasms were reviewed. Statistical analysis was performed via an unpaired Student t test and the Fisher exact test. Results: Fourteen patients were identified, 7 with anal intraepithelial neoplasms (group 1) and 7 with anal carcinoma (group 2). Human papillomavirus was detected in 100{\%} of patients in group 1 and in 67{\%} of patients in group 2. There was no significant difference in the level of immunosuppression as assessed by the CD4 counts (266.9 ± 48.5 vs. 274.7 ± 92.0 cell/cμl; P = .94) and viral loads (19,243 ± 18,034 vs. 67,140 ± 39,570 RNA/mL; P = .29) between groups 1 and 2, respectively. Group 2 had been HIV positive for a significantly longer period of time (12.6 ± 2.3 y) compared with group 1 (5.9 ± 2.0 y, P = .05). Conclusions: The most significant factor for the development of invasive anal carcinoma in patients with HIV is duration of disease. As a result of improved long-term survival secondary to new HIV therapy, anal invasive carcinoma will become an increasing problem.",
keywords = "Anal carcinoma, Bowen's disease, HIV, Immune status",
author = "Fagan, {Shawn P.} and Bellows, {Charles F.} and Daniel Albo and Maria Rodriquez-Barradas and Mark Feanny and Awad, {Samir S.} and Berger, {David H.}",
year = "2005",
month = "11",
day = "1",
doi = "10.1016/j.amjsurg.2005.07.011",
language = "English (US)",
volume = "190",
pages = "732--735",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Length of human immunodeficiency virus disease and not immune status is a risk factor for development of anal carcinoma

AU - Fagan, Shawn P.

AU - Bellows, Charles F.

AU - Albo, Daniel

AU - Rodriquez-Barradas, Maria

AU - Feanny, Mark

AU - Awad, Samir S.

AU - Berger, David H.

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Background: The anal epithelium is subject to dysplastic change in patients with human immunodeficiency virus (HIV). We sought to determine if the duration of HIV disease or the patient's immune status were associated with the development of anal carcinoma. Methods: HIV-positive patients diagnosed with anal neoplasms were reviewed. Statistical analysis was performed via an unpaired Student t test and the Fisher exact test. Results: Fourteen patients were identified, 7 with anal intraepithelial neoplasms (group 1) and 7 with anal carcinoma (group 2). Human papillomavirus was detected in 100% of patients in group 1 and in 67% of patients in group 2. There was no significant difference in the level of immunosuppression as assessed by the CD4 counts (266.9 ± 48.5 vs. 274.7 ± 92.0 cell/cμl; P = .94) and viral loads (19,243 ± 18,034 vs. 67,140 ± 39,570 RNA/mL; P = .29) between groups 1 and 2, respectively. Group 2 had been HIV positive for a significantly longer period of time (12.6 ± 2.3 y) compared with group 1 (5.9 ± 2.0 y, P = .05). Conclusions: The most significant factor for the development of invasive anal carcinoma in patients with HIV is duration of disease. As a result of improved long-term survival secondary to new HIV therapy, anal invasive carcinoma will become an increasing problem.

AB - Background: The anal epithelium is subject to dysplastic change in patients with human immunodeficiency virus (HIV). We sought to determine if the duration of HIV disease or the patient's immune status were associated with the development of anal carcinoma. Methods: HIV-positive patients diagnosed with anal neoplasms were reviewed. Statistical analysis was performed via an unpaired Student t test and the Fisher exact test. Results: Fourteen patients were identified, 7 with anal intraepithelial neoplasms (group 1) and 7 with anal carcinoma (group 2). Human papillomavirus was detected in 100% of patients in group 1 and in 67% of patients in group 2. There was no significant difference in the level of immunosuppression as assessed by the CD4 counts (266.9 ± 48.5 vs. 274.7 ± 92.0 cell/cμl; P = .94) and viral loads (19,243 ± 18,034 vs. 67,140 ± 39,570 RNA/mL; P = .29) between groups 1 and 2, respectively. Group 2 had been HIV positive for a significantly longer period of time (12.6 ± 2.3 y) compared with group 1 (5.9 ± 2.0 y, P = .05). Conclusions: The most significant factor for the development of invasive anal carcinoma in patients with HIV is duration of disease. As a result of improved long-term survival secondary to new HIV therapy, anal invasive carcinoma will become an increasing problem.

KW - Anal carcinoma

KW - Bowen's disease

KW - HIV

KW - Immune status

UR - http://www.scopus.com/inward/record.url?scp=26844552909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844552909&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2005.07.011

DO - 10.1016/j.amjsurg.2005.07.011

M3 - Article

VL - 190

SP - 732

EP - 735

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 5

ER -